For about 7 years, there has been one FDA approved treatment for neurotrophic keratitis (NK): Oxervate (cenegermin-bkbj, Dompe). Before that, there was nothing. Now pharmaceutical options for NK—and persistent epithelial corneal defect (PCED) more generally—in the pipeline number about a half dozen.
An emphasis on sustainability in healthcare has gained momentum in recent years. In this article, a group of glaucoma specialists who are experts in sustainability offered their perspectives on how to make meaningful changes in a clinical practice.
“As healthcare practitioners, we’re constantly looking to provide the highest quality of care. We research to learn more about materials, investigate new technologies, and query for data on efficacy measures,” said Karolinne Rocha, MD, PhD, before introducing the articles in this issue’s Refractive section.
Cornea Editor Julie Schallhorn, MD, gave a preview of the articles in the section and talked about the current climate for institutional funding for research.
Chief Medical Editor Sumit “Sam” Garg, MD, shared his thoughts on the theme of “Changing mindsets” in his introduction to the issue.
Ophthalmology is constantly evolving to meet new and unmet needs. EyeWorld asked members of its Cataract Editorial Board and the ASCRS Cataract Clinical Committee to weigh in on: If I could ask industry to produce one new product, this is what it would be and why.
Three surgeons weighed in on the pros and cons of different lens materials as well as what may be coming in the future.
With dry eye presenting as an increasingly common issue, many companies are exploring options to treat these patients. New products in development are seeking to address different aspects of dry eye, with various amechanisms of action. Three specialists discussed some of these.
While the treatment mainstays for lowering and/or maintaining a target IOP are achieved with surgery, laser, or pharmaceuticals, patients often ask what else they can do. Several physicians spoke to EyeWorld about lifestyle changes that they recommend as an addition to traditional glaucoma therapies.
Workforce engagement expert and leadership trainer Joe Mull, who served as the keynote speaker at the 2025 ASOA Annual Meeting in Los Angeles, California, dispelled myths and shared the conditions needed for a destination workplace.